- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial
- Study type descriptors: Interventional
- Study aim: To assess the safety and neutralizing activity of one dose of AZD3152 compared with one dose of placebo in adults with immunocompromised conditions. Additionally, the study aims to evaluate the efficacy of AZD3152 in reducing the severity of a COVID-19 infection in this population
- Number of participants enrolled: 116
- Study enrolling from to
Study Data
- Adults
- Elderly
- Immunocompromised host
- Fragile population
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- AZD3152
- Monoclonal antibodies
External Links
Other information
Funders:
- AstraZeneca
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to